ClinicalTrials.gg
RecruitingNCT05586776DECREASE SSIUpdated Jul 21, 2026

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

A Phase 4 interventional study of 4% Chlorhexidine Gluconate and 2% Mupirocin in Surgical Site Infection, sponsored by University of California, Irvine. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by University of California, Irvine · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.

Planned enrollment
7th of 177
2,700 · median 208
Started
2023
with 8 others
Phase 4
39 of 202
7 open now
Primary completion
2027-06
later than 18 of 33 live
Registered
171st of 202
by date

Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 7th largest by planned enrollment of the 177 interventional ones that give a count, is one of 9 that started in 2023, is one of 39 in phase 4, reaches primary completion later than 18 of the 33 other live ones, and was the 171st registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Surgical Wound Infection with a site in United States, or all of them as a file.
02

Study summary

The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.

03

Conditions studied

  • Surgical Site Infection

Keywords

  • Surgical Site Infection
  • SSI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Recent open (not solely laparoscopic) surgery involving an abdominal incision within the past 14 days. For cesarean section, recruitment restricted to ≥ 40.
  • Able to communicate regularly by phone
  • Able to bathe, shower or have this task performed by a caregiver

Exclusion criteria

Exclusion Criteria:

  • Transfer to an acute care hospital
  • Discharged to receive end-of-life hospice measures
  • Discharged more than 14 days after surgery
  • Allergic to mupirocin and/or chlorhexidine
  • Active infection at enrollment*

    *Refers to

    1. Infections requiring systemic antibacterial agents, so viral illness (e.g., COVID, flu) is not an exclusion.
    2. Topical antibacterial agents do not count toward exclusion (e.g., topical products for acne)
    3. Prophylactic antibacterial agents do not count toward exclusion
  • Surgical incision not closed at discharge
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,700 participants (estimated)

Study arms

  • Active comparator
    Decolonization

    Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).

    Drug: 4% Chlorhexidine Gluconate · Drug: 2% Mupirocin

  • Placebo comparator
    Routine Care

    Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.

    Drug: Soap Without Antiseptic Properties (Placebo) · Drug: Placebo Nasal Ointment

Interventions

  • DrugChlorhexidine gluconateStudies of Chlorhexidine gluconateChlorhexidine gluconate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Used for daily showering/bathing for 30 days after hospital discharge.

  • DrugMupirocinStudies of MupirocinMupirocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.

  • DrugSoap Without Antiseptic Properties (Placebo)

    Used for daily showering/bathing for 30 days after hospital discharge.

  • DrugPlacebo Nasal Ointment

    Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.

06

What researchers measure

Primary outcomes

  1. Time to First Post-Discharge Surgical Site Infection

    Time frame: Within 30 Days of Hospital Discharge

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — A data request form will be provided to any researcher requesting data from the DECREASE SSI trial This data request form will request the hypothesis/goal of the research, the planned use of the data, and the requested data elements (deidentified only). Any data provided will include the stipulation that use is limited to research purposes only. Requests will not be granted for pursuits directly specified in the grant. If the data request overlaps with additional ongoing post-grant pursuits either by this team or another investigative team that requested the data for a given purpose, a discussion will be pursued toward the potential for joint collaboration.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: 3 years from publication

Access criteria: Pending

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.

Of 45 non-industry phase 4 interventional studies under Surgical Wound Infection, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's planned 53 months is above that.

Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 16 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2022
First posted
Oct 19, 2022
StartActual
Jan 17, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05586776
Collaborators
University of California, Davis, University of California, San Francisco, University of Massachusetts, Amherst, Hoag Memorial Hospital Presbyterian
Responsible party
Susan Huang (Professor, Division of Infectious Diseases and Medical Director, Epidemiology and Infection Prevention, University of California, Irvine) — Principal investigator
First posted
Oct 19, 2022
Start date
Jan 17, 2023
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Susan Huang, MD, MPH
Contact
sshuang@hs.uci.edu
(949) 824-5073
Raveena Singh, MA
Contact
ravsingh@hs.uci.edu
(949) 824-9285
Susan Huang, MD, MPH
principal investigator · University of California, Irvine
Deborah Yokoe, MD, MPH
study director · University of California, San Francisco
Stuart Cohen, MD
study director · University of California, Davis

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Chlorhexidine gluconate · Mupirocin

Start the discussion